Schedule of the Effect of Share-based Compensation on the Statements of Operations (Details) - Chemomab Therapeutics Ltd [Member] - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Share-based compensation expenses | $ 87 | $ 79 | $ 221 | $ 245 | $ 623 | $ 617 | $ 1,491 |
| Research and Development Arrangement [Member] | |||||||
| Share-based compensation expenses | 37 | (39) | 79 | 22 | 158 | 401 | 407 |
| General and Administrative [Member] | |||||||
| Share-based compensation expenses | $ 50 | $ 118 | $ 142 | $ 223 | $ 465 | $ 216 | $ 1,084 |